15 July 2023
PolygenRx Announces Collaborative Agreement with Atherion Bioresearch Inc.
PolygenRx will bring its pharmagenic enrichment platform to the suite of clinical trial services offered by Atherion
Today PolygenRx announced that it has entered into a collaborative agreement with Atherion Bioresearch, Inc. atherion-bioresearch.com. Atherion is a full-service clinical research organization (CRO) offering bespoke solutions for accelerating pharmaceutical development. PolygenRx CEO, Professor Cairns said, "We look forward to complementing this highly experienced team’s capability for supporting leading edge clinical trials using our ground-breaking Pharmagenic Enrichment platform."
PolygenRx can dramatically reduce the cost and risk of late-stage clinical trials by genetically enriching for treatment responders. We can support the development of undifferentiated assets into targeted therapies. To learn how to tackle drug response heterogeneity with our Precision Medicine strategy, email email@example.com.